Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes
Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRN...
Saved in:
Published in | Oncotarget Vol. 5; no. 20; pp. 9864 - 9876 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Impact Journals LLC
30.10.2014
|
Subjects | |
Online Access | Get full text |
ISSN | 1949-2553 1949-2553 |
DOI | 10.18632/oncotarget.2454 |
Cover
Abstract | Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis- and trans-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome. |
---|---|
AbstractList | Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for
cis
- and
trans
-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA
HOTAIR
was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA
HOTAIRM1
was significantly overexpressed in the basal-like subgroup. Estrogen receptor
(ESR1)
expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome. Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis- and trans-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome. Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis- and trans-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome.Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis- and trans-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome. |
Author | Esteva, Francisco J. Malouf, Gabriel G. Spano, Jean-Philippe Khayat, David Meric-Bernstam, Funda Zhang, Jianping Weinstein, John N. Chen, Yunxin Yao, Hui Valero, Vicente Su, Xiaoping |
AuthorAffiliation | 3 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France 1 Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5 Breast Medical Oncology Program, New York University Cancer Institute, New York, NY, USA |
AuthorAffiliation_xml | – name: 2 Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France – name: 1 Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – name: 4 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – name: 5 Breast Medical Oncology Program, New York University Cancer Institute, New York, NY, USA – name: 3 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA |
Author_xml | – sequence: 1 givenname: Xiaoping surname: Su fullname: Su, Xiaoping organization: Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 2 givenname: Gabriel G. surname: Malouf fullname: Malouf, Gabriel G. organization: Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France – sequence: 3 givenname: Yunxin surname: Chen fullname: Chen, Yunxin organization: Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 4 givenname: Jianping surname: Zhang fullname: Zhang, Jianping organization: Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 5 givenname: Hui surname: Yao fullname: Yao, Hui organization: Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 6 givenname: Vicente surname: Valero fullname: Valero, Vicente organization: Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 7 givenname: John N. surname: Weinstein fullname: Weinstein, John N. organization: Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 8 givenname: Jean-Philippe surname: Spano fullname: Spano, Jean-Philippe organization: Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France – sequence: 9 givenname: Funda surname: Meric-Bernstam fullname: Meric-Bernstam, Funda organization: Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 10 givenname: David surname: Khayat fullname: Khayat, David organization: Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France – sequence: 11 givenname: Francisco J. surname: Esteva fullname: Esteva, Francisco J. organization: Breast Medical Oncology Program, New York University Cancer Institute, New York, NY, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25296969$$D View this record in MEDLINE/PubMed |
BookMark | eNp1UVtLHDEYDbJSt1vffZI8-jJ2cpudvAiyVC1IBVF8DNnMN7spmWRNMsL--8bLWlvwC3w5kHOBnK9o4oMHhI5IfUrahtHvwZuQdVxBPqVc8D00JZLLigrBJh_wATpM6XddRvB5S-UXdEAFlU05U_SwCMMmwhp8sk-Atddum2zCoccu-BUumZUJnS3w9td5wtbj9Thoj5cRdMrYaG8gYuOst0Y7nMZl3m4gfUP7vXYJDt_uGbq_-HG3uKquby5_Ls6vK8MbmisjgVAtWyZF3S0ZGNazsjXMiehEq1tBBHR10_dtT4kQXMiaSyEZ6dsGxJzN0Nmr72ZcDtAZ8DlqpzbRDjpuVdBW_fvi7VqtwpPiVEjOWTE4eTOI4XGElNVgkwHntIcwJkUayiXjjJNCPf6Y9R6y-81CaF4JJoaUIvTK2KyzDc_R1ilSq5fm1N_m1HNzRVj_J9x5fyr5A9RfoJc |
CitedBy_id | crossref_primary_10_1042_BCJ20170664 crossref_primary_10_1016_j_gene_2020_145063 crossref_primary_10_1371_journal_pone_0163238 crossref_primary_10_3389_fgene_2018_00471 crossref_primary_10_3892_ol_2016_4770 crossref_primary_10_1111_jog_13840 crossref_primary_10_1038_srep37821 crossref_primary_10_18632_oncotarget_24591 crossref_primary_10_1002_jcb_27770 crossref_primary_10_1007_s12253_018_00570_4 crossref_primary_10_18632_oncotarget_9880 crossref_primary_10_1002_jcla_22193 crossref_primary_10_18632_oncotarget_19727 crossref_primary_10_1111_and_13897 crossref_primary_10_3390_ijms22126374 crossref_primary_10_1007_s11033_021_06847_3 crossref_primary_10_18632_oncotarget_14313 crossref_primary_10_1038_labinvest_2015_80 crossref_primary_10_1186_s12967_018_1640_2 crossref_primary_10_1186_s13045_018_0596_2 crossref_primary_10_1158_1078_0432_CCR_15_1555 crossref_primary_10_4048_jbc_2018_21_e41 crossref_primary_10_1093_hmg_ddw177 crossref_primary_10_15252_emmm_201606198 crossref_primary_10_18632_oncotarget_6420 crossref_primary_10_1016_j_bbagen_2017_04_007 crossref_primary_10_1089_gtmb_2019_0102 crossref_primary_10_3390_ijms26010127 crossref_primary_10_1261_rna_073254_119 crossref_primary_10_18632_oncotarget_14304 crossref_primary_10_3390_cells12081159 crossref_primary_10_3390_ijms23010201 crossref_primary_10_1002_jcp_25997 crossref_primary_10_3390_sci2020024 crossref_primary_10_1007_s10549_016_3826_8 crossref_primary_10_1016_j_bbcan_2022_188747 crossref_primary_10_1049_syb2_12020 crossref_primary_10_1158_0008_5472_CAN_16_2634 crossref_primary_10_3390_cancers14092115 crossref_primary_10_1093_nar_gkw966 crossref_primary_10_1016_j_omtn_2021_08_005 crossref_primary_10_1093_gigascience_giz145 crossref_primary_10_1007_s40139_017_0122_1 crossref_primary_10_1080_14737159_2018_1538794 crossref_primary_10_3727_096504016X14618564639178 crossref_primary_10_3390_ijms23063189 crossref_primary_10_2217_epi_2015_0012 crossref_primary_10_1038_s41419_020_2416_1 crossref_primary_10_1158_0008_5472_CAN_15_3284 crossref_primary_10_1038_s41419_023_05609_2 crossref_primary_10_1186_s12967_016_1025_3 crossref_primary_10_1007_s10911_022_09511_z crossref_primary_10_1016_j_ejmech_2017_07_075 crossref_primary_10_1016_j_biopha_2018_08_105 crossref_primary_10_1007_s13237_017_0201_z crossref_primary_10_18632_oncotarget_24403 crossref_primary_10_2147_JHC_S415318 crossref_primary_10_1002_cam4_1523 crossref_primary_10_1007_s13311_019_00799_0 crossref_primary_10_1038_s41523_019_0144_4 crossref_primary_10_18632_oncotarget_3457 crossref_primary_10_1038_s42003_022_03559_7 crossref_primary_10_18632_oncotarget_22063 crossref_primary_10_3390_ijms17091485 crossref_primary_10_18632_aging_102205 crossref_primary_10_1016_j_ymthe_2018_08_026 crossref_primary_10_1038_s41388_020_1365_6 crossref_primary_10_3390_genes12121978 crossref_primary_10_3892_mmr_2017_7606 crossref_primary_10_3390_ijms19092711 crossref_primary_10_1186_s13058_015_0557_4 crossref_primary_10_18632_oncotarget_4419 crossref_primary_10_3892_or_2017_5821 crossref_primary_10_1016_j_bbrc_2016_05_031 crossref_primary_10_1016_j_bbagrm_2019_04_005 crossref_primary_10_1038_s41598_021_86923_7 crossref_primary_10_1016_j_ijbiomac_2017_03_021 crossref_primary_10_1039_C7RA12131H crossref_primary_10_1158_0008_5472_CAN_17_3486 crossref_primary_10_3389_fonc_2024_1458588 crossref_primary_10_3389_fonc_2021_752579 crossref_primary_10_12688_f1000research_27393_2 crossref_primary_10_1158_0008_5472_CAN_15_0506 crossref_primary_10_12688_f1000research_27393_3 crossref_primary_10_3389_fcell_2020_00368 crossref_primary_10_1186_s12943_019_1021_3 crossref_primary_10_3390_sci3020026 crossref_primary_10_3390_ijms17081357 crossref_primary_10_1007_s13277_015_4572_y crossref_primary_10_1111_jcmm_12681 crossref_primary_10_3390_ncrna4010007 crossref_primary_10_1016_j_compbiolchem_2018_11_008 crossref_primary_10_18632_oncotarget_8192 crossref_primary_10_7717_peerj_8797 crossref_primary_10_1038_srep41960 crossref_primary_10_1038_s41598_017_17996_6 crossref_primary_10_1016_j_ygeno_2021_07_015 crossref_primary_10_1038_s41598_020_65109_7 crossref_primary_10_1111_cge_13502 crossref_primary_10_3390_pharmaceutics15082096 crossref_primary_10_1007_s13277_015_3714_6 crossref_primary_10_1038_s41598_020_71062_2 crossref_primary_10_1016_j_prp_2019_03_033 crossref_primary_10_1093_bfgp_elv049 crossref_primary_10_18632_oncotarget_13384 crossref_primary_10_7717_peerj_13641 crossref_primary_10_18632_oncotarget_7559 crossref_primary_10_3390_cancers13143530 crossref_primary_10_3390_cells8060605 crossref_primary_10_1530_ERC_17_0548 crossref_primary_10_1093_bioinformatics_btad276 crossref_primary_10_1002_jcb_27584 crossref_primary_10_1002_ijc_33539 crossref_primary_10_1126_sciadv_1600220 crossref_primary_10_1371_journal_pone_0314973 crossref_primary_10_1186_s12943_017_0580_4 crossref_primary_10_3390_cancers13215350 crossref_primary_10_18632_oncotarget_11998 crossref_primary_10_3892_ijo_2015_3292 crossref_primary_10_1002_1878_0261_12489 crossref_primary_10_18632_oncotarget_6859 crossref_primary_10_18632_oncotarget_9608 crossref_primary_10_1186_s12935_018_0674_0 crossref_primary_10_18632_oncotarget_9622 crossref_primary_10_1016_j_bone_2015_05_026 crossref_primary_10_1002_jcp_27036 crossref_primary_10_1016_j_ebiom_2016_02_028 crossref_primary_10_3389_fgene_2022_932060 crossref_primary_10_18632_oncotarget_10213 crossref_primary_10_18632_oncotarget_17409 crossref_primary_10_1039_C6MB00585C crossref_primary_10_1007_s10142_023_01112_1 crossref_primary_10_1186_s12967_020_02320_0 crossref_primary_10_3390_ijms21197407 crossref_primary_10_1093_bib_bbv114 crossref_primary_10_3892_etm_2017_5573 crossref_primary_10_18632_oncotarget_5399 crossref_primary_10_1038_s41598_017_00823_3 crossref_primary_10_1186_s12935_021_02362_4 crossref_primary_10_1007_s44178_022_00009_6 crossref_primary_10_1007_s10753_023_01919_x crossref_primary_10_3390_ijms19010123 crossref_primary_10_1038_s41598_020_69905_z crossref_primary_10_3390_cancers14235980 crossref_primary_10_1002_jcb_29621 crossref_primary_10_1007_s13277_016_5426_y crossref_primary_10_1039_C7RA12042G crossref_primary_10_18632_oncotarget_14522 crossref_primary_10_1016_j_gene_2020_145033 crossref_primary_10_1172_jci_insight_168988 crossref_primary_10_1186_s12967_015_0556_3 crossref_primary_10_1139_bcb_2018_0039 crossref_primary_10_1186_s12885_019_6338_1 |
Cites_doi | 10.1007/s10549-012-2314-z 10.1038/ng.131 10.1182/blood-2008-06-162164 10.1073/pnas.0408974102 10.18632/oncotarget.1769 10.1186/bcr2937 10.1214/07-AOAS101 10.1073/pnas.191367098 10.1158/0008-5472.CAN-13-1896 10.1101/gad.1800909 10.1016/j.tig.2011.06.009 10.1093/hmg/ddq362 10.1038/nsmb.2591 10.1038/cr.2010.114 10.1038/nature07672 10.1200/JCO.2008.18.1370 10.1080/07357900701784238 10.1038/nbt.1630 10.1038/nrg2521 10.1073/pnas.0506580102 10.1016/j.cell.2010.09.001 10.1016/j.gde.2011.01.020 10.1101/gr.132159.111 10.1172/JCI60534 10.1002/emmm.201100122 10.1371/journal.pcbi.1000176 10.1016/j.cell.2012.02.008 10.1073/pnas.1933744100 10.1101/gad.17446611 10.1371/journal.pgen.0020047 10.1038/nature08975 10.1038/nbt.1914 10.1038/nmeth.1179 10.1038/35021093 10.1016/j.tcb.2011.04.001 10.1038/nature07107 10.1007/s10911-012-9245-5 10.1186/gb-2010-11-10-r106 |
ContentType | Journal Article |
Copyright | Copyright: © 2014 Su et al. 2014 |
Copyright_xml | – notice: Copyright: © 2014 Su et al. 2014 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.18632/oncotarget.2454 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1949-2553 |
EndPage | 9876 |
ExternalDocumentID | PMC4259443 25296969 10_18632_oncotarget_2454 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA016672 – fundername: NCI NIH HHS grantid: P50 CA100632 – fundername: NCATS NIH HHS grantid: UL1 TR000371 – fundername: NCATS NIH HHS grantid: UL1TR000371 |
GroupedDBID | --- 53G AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK FRJ GX1 HYE KQ8 M48 OK1 PGMZT RPM CGR CUY CVF ECM EIF M~E NPM 7X8 5PM |
ID | FETCH-LOGICAL-c462t-c9e12a983950db3ec3f33ecae715d58a8515ed06ff8f21554590495931f86e573 |
IEDL.DBID | M48 |
ISSN | 1949-2553 |
IngestDate | Thu Aug 21 17:51:38 EDT 2025 Thu Jul 10 21:03:19 EDT 2025 Sat Sep 28 07:56:40 EDT 2024 Thu Apr 24 23:13:16 EDT 2025 Tue Jul 01 02:40:20 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 20 |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c462t-c9e12a983950db3ec3f33ecae715d58a8515ed06ff8f21554590495931f86e573 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.18632/oncotarget.2454 |
PMID | 25296969 |
PQID | 1624934341 |
PQPubID | 23479 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4259443 proquest_miscellaneous_1624934341 pubmed_primary_25296969 crossref_citationtrail_10_18632_oncotarget_2454 crossref_primary_10_18632_oncotarget_2454 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-10-30 |
PublicationDateYYYYMMDD | 2014-10-30 |
PublicationDate_xml | – month: 10 year: 2014 text: 2014-10-30 day: 30 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Oncotarget |
PublicationTitleAlternate | Oncotarget |
PublicationYear | 2014 |
Publisher | Impact Journals LLC |
Publisher_xml | – name: Impact Journals LLC |
References | Huang (22) 2010; 143 Hayes (34) 2003; 100 Jeffrey (9) 2001; 98 Mattick (13) 2009; 10 Gregori (15) 2012; 136 Shiekhattar (16) 2011; 21 Greenwood (30) 2011; 3 Creighton (25) 2012; 6 Knowles (24) 2012; 22 Shu (5) 2014 Lander (40) 2005; 102 Ma (11) 2012; 17 Bell (20) 2012; 148 Lee (33) 2014; 74 Akslen (8) 2000; 406 Bejerano (19) 2010; 28 Huber (38) 2010; 11 Rimm (36) 2011; 13 Wang (4) 2014 Huang (37) 2008; 5 Jaffe (27) 2008; 454 Chang (2) 2011; 21 Rinn (14) 2010; 464 Belgard (12) 2010; 19 Cassady (39) 2009; 458 Rinn (23) 2011; 25 Yang (28) 2006; 2 Tibshirani (41) 2007; 1 Aben (21) 2008; 40 Buchholz (31) 2005; 102 Carey (18) 2008; 26 Mattick (29) 2008; 4 Shiekhattar (17) 2011; 27 Liu (6) 2013; 20 Kominsky (35) 2011; 29 Spector (1) 2009; 23 Hu (10) 2009; 27 Newburger (32) 2009; 113 Zhang (26) 2010; 20 Farrar (3) 2014; 5 Polyak (7) 2011; 121 19043537 - PLoS Comput Biol. 2008 Nov;4(11):e1000176 19204204 - J Clin Oncol. 2009 Mar 10;27(8):1160-7 22350981 - J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):33-42 20979621 - Genome Biol. 2010;11(10):R106 23124417 - Breast Cancer Res Treat. 2012 Dec;136(3):875-83 22385965 - Cell. 2012 Mar 2;148(5):1015-28 16683030 - PLoS Genet. 2006 Apr;2(4):e47 19144990 - Blood. 2009 Mar 12;113(11):2526-34 21888627 - Breast Cancer Res. 2011;13(5):R85 19571179 - Genes Dev. 2009 Jul 1;23(13):1494-504 14500907 - Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 15914550 - Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20 21890647 - Genes Dev. 2011 Sep 15;25(18):1915-27 11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 21550244 - Trends Cell Biol. 2011 Jun;21(6):354-61 23728290 - Nat Struct Mol Biol. 2013 Jul;20(7):908-13 19182780 - Nature. 2009 Mar 12;458(7235):223-7 18204455 - Nat Methods. 2008 Feb;5(2):183-8 19188922 - Nat Rev Genet. 2009 Mar;10(3):155-9 22955988 - Genome Res. 2012 Sep;22(9):1775-89 20680032 - Cell Res. 2010 Oct;20(10):1109-16 18600261 - Nature. 2008 Aug 7;454(7205):766-70 18181038 - Cancer Invest. 2008 Feb;26(1):1-10 21831473 - Trends Genet. 2011 Oct;27(10):433-9 21965334 - J Clin Invest. 2011 Oct;121(10):3786-8 20436461 - Nat Biotechnol. 2010 May;28(5):495-501 20887892 - Cell. 2010 Oct 1;143(1):46-58 20393566 - Nature. 2010 Apr 15;464(7291):1071-6 24519926 - Oncotarget. 2014 Feb 15;5(3):764-74 21804560 - Nat Biotechnol. 2011 Aug;29(8):742-9 21337521 - EMBO Mol Med. 2011 Mar;3(3):167-80 21330130 - Curr Opin Genet Dev. 2011 Apr;21(2):194-8 24631686 - Biochem Biophys Res Commun. 2014 Apr 4;446(2):448-53 18438407 - Nat Genet. 2008 Jun;40(6):703-6 20798109 - Hum Mol Genet. 2010 Oct 15;19(R2):R162-8 10963602 - Nature. 2000 Aug 17;406(6797):747-52 22956860 - Biologics. 2012;6:289-97 24491801 - Cancer Res. 2014 Mar 15;74(6):1705-17 24388988 - Biochem Biophys Res Commun. 2014 Jun 6;448(3):315-22 16199517 - Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 |
References_xml | – volume: 136 start-page: 875 year: 2012 ident: 15 article-title: Association of large noncoding RNAexpression and its downstream intergenic CpG island methylation with survival in breast cancer. publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-2314-z – volume: 40 start-page: 703 year: 2008 ident: 21 article-title: Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. publication-title: Nat Genet doi: 10.1038/ng.131 – volume: 113 start-page: 2526 year: 2009 ident: 32 article-title: A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. publication-title: Blood doi: 10.1182/blood-2008-06-162164 – volume: 102 start-page: 8315 year: 2005 ident: 31 article-title: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0408974102 – volume: 5 start-page: 764 year: 2014 ident: 3 article-title: Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. publication-title: Oncotarget doi: 10.18632/oncotarget.1769 – volume: 13 start-page: R85 year: 2011 ident: 36 article-title: Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. publication-title: Breast Cancer Res doi: 10.1186/bcr2937 – volume: 1 start-page: 107 year: 2007 ident: 41 article-title: On testing the significance of gene sets. publication-title: Ann Appl Stat doi: 10.1214/07-AOAS101 – volume: 98 start-page: 10869 year: 2001 ident: 9 article-title: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.191367098 – volume: 74 start-page: 1705 year: 2014 ident: 33 article-title: and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-1896 – volume: 23 start-page: 1494 year: 2009 ident: 1 article-title: Long noncoding RNAs: functional surprises from the RNA world. publication-title: Genes Dev doi: 10.1101/gad.1800909 – volume: 27 start-page: 433 year: 2011 ident: 17 article-title: Noncoding RNAs and enhancers: complications of a long-distance relationship publication-title: Trends Genet doi: 10.1016/j.tig.2011.06.009 – volume: 19 start-page: R162 year: 2010 ident: 12 article-title: Transcribed dark matter: meaning or myth? publication-title: Hum Mol Genet doi: 10.1093/hmg/ddq362 – volume: 20 start-page: 908 year: 2013 ident: 6 article-title: Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. publication-title: Nat Struct Mol Biol doi: 10.1038/nsmb.2591 – volume: 20 start-page: 1109 year: 2010 ident: 26 article-title: Role of H3K27 methylation in the regulation of lncRNA expression. publication-title: Cell Res doi: 10.1038/cr.2010.114 – volume: 458 start-page: 223 year: 2009 ident: 39 article-title: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. publication-title: Nature doi: 10.1038/nature07672 – start-page: pii year: 2014 ident: 4 article-title: Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells publication-title: Biochem Biophys Res Commun – volume: 27 start-page: 1160 year: 2009 ident: 10 article-title: Supervised risk predictor of breast cancer based on intrinsic subtypes. publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.1370 – volume: 6 start-page: 289 year: 2012 ident: 25 article-title: The molecular profile of luminal B breast cancer. publication-title: Biologics – volume: 26 start-page: 1 year: 2008 ident: 18 article-title: Molecular subtypes in breast cancer evaluation and management: divide and conquer. publication-title: Cancer Invest doi: 10.1080/07357900701784238 – volume: 28 start-page: 495 year: 2010 ident: 19 article-title: GREAT improves functional interpretation of cis-regulatory regions. publication-title: Nat Biotechnol doi: 10.1038/nbt.1630 – volume: 10 start-page: 155 year: 2009 ident: 13 article-title: Long non-coding RNAs: insights into functions. publication-title: Nat Rev Genet doi: 10.1038/nrg2521 – volume: 102 start-page: 15545 year: 2005 ident: 40 article-title: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0506580102 – volume: 143 start-page: 46 year: 2010 ident: 22 article-title: Long noncoding RNAs with enhancer-like function in human cells. publication-title: Cell doi: 10.1016/j.cell.2010.09.001 – volume: 21 start-page: 194 year: 2011 ident: 16 article-title: Long non-coding RNAs and enhancers. publication-title: Curr Opin Genet Dev doi: 10.1016/j.gde.2011.01.020 – volume: 22 start-page: 1775 year: 2012 ident: 24 article-title: The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. publication-title: Genome Res doi: 10.1101/gr.132159.111 – volume: 121 start-page: 3786 year: 2011 ident: 7 article-title: Heterogeneity in breast cancer. publication-title: J Clin Invest doi: 10.1172/JCI60534 – volume: 3 start-page: 167 year: 2011 ident: 30 article-title: ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. publication-title: EMBO Mol Med doi: 10.1002/emmm.201100122 – volume: 4 start-page: e1000176 year: 2008 ident: 29 article-title: Differentiating protein-coding and noncoding RNA: challenges and ambiguities. publication-title: PLoS Comput Biol doi: 10.1371/journal.pcbi.1000176 – volume: 148 start-page: 1015 year: 2012 ident: 20 article-title: Slug and Sox9 cooperatively determine the mammary stem cell state. publication-title: Cell doi: 10.1016/j.cell.2012.02.008 – volume: 100 start-page: 11606 year: 2003 ident: 34 article-title: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1933744100 – start-page: pii year: 2014 ident: 5 article-title: The long non-coding RNA-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1 publication-title: Biochem Biophys Res Commun – volume: 25 start-page: 1915 year: 2011 ident: 23 article-title: Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. publication-title: Genes Dev doi: 10.1101/gad.17446611 – volume: 2 start-page: e47 year: 2006 ident: 28 article-title: Complex Loci in human and mouse genomes. publication-title: PLoS Genet doi: 10.1371/journal.pgen.0020047 – volume: 464 start-page: 1071 year: 2010 ident: 14 article-title: Long non-coding RNAreprograms chromatin state to promote cancer metastasis. publication-title: Nature doi: 10.1038/nature08975 – volume: 29 start-page: 742 year: 2011 ident: 35 article-title: Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. publication-title: Nat Biotechnol doi: 10.1038/nbt.1914 – volume: 5 start-page: 183 year: 2008 ident: 37 article-title: Whole-genome sequencing and variant discovery in C. elegans publication-title: Nat Methods doi: 10.1038/nmeth.1179 – volume: 406 start-page: 747 year: 2000 ident: 8 article-title: Molecular portraits of human breast tumours. publication-title: Nature doi: 10.1038/35021093 – volume: 21 start-page: 354 year: 2011 ident: 2 article-title: Long noncoding RNAs and human disease. publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2011.04.001 – volume: 454 start-page: 766 year: 2008 ident: 27 article-title: Genome-scale DNA methylation maps of pluripotent and differentiated cells. publication-title: Nature doi: 10.1038/nature07107 – volume: 17 start-page: 33 year: 2012 ident: 11 article-title: Non-coding RNAs as regulators of mammary development and breast cancer. publication-title: J Mammary Gland Biol Neoplasia doi: 10.1007/s10911-012-9245-5 – volume: 11 start-page: R106 year: 2010 ident: 38 article-title: Differential expression analysis for sequence count data. publication-title: Genome Biol doi: 10.1186/gb-2010-11-10-r106 – reference: 20436461 - Nat Biotechnol. 2010 May;28(5):495-501 – reference: 21330130 - Curr Opin Genet Dev. 2011 Apr;21(2):194-8 – reference: 11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 – reference: 23728290 - Nat Struct Mol Biol. 2013 Jul;20(7):908-13 – reference: 19182780 - Nature. 2009 Mar 12;458(7235):223-7 – reference: 21337521 - EMBO Mol Med. 2011 Mar;3(3):167-80 – reference: 18204455 - Nat Methods. 2008 Feb;5(2):183-8 – reference: 21965334 - J Clin Invest. 2011 Oct;121(10):3786-8 – reference: 24491801 - Cancer Res. 2014 Mar 15;74(6):1705-17 – reference: 20393566 - Nature. 2010 Apr 15;464(7291):1071-6 – reference: 20680032 - Cell Res. 2010 Oct;20(10):1109-16 – reference: 18438407 - Nat Genet. 2008 Jun;40(6):703-6 – reference: 24631686 - Biochem Biophys Res Commun. 2014 Apr 4;446(2):448-53 – reference: 24519926 - Oncotarget. 2014 Feb 15;5(3):764-74 – reference: 22955988 - Genome Res. 2012 Sep;22(9):1775-89 – reference: 22956860 - Biologics. 2012;6:289-97 – reference: 20798109 - Hum Mol Genet. 2010 Oct 15;19(R2):R162-8 – reference: 19571179 - Genes Dev. 2009 Jul 1;23(13):1494-504 – reference: 19144990 - Blood. 2009 Mar 12;113(11):2526-34 – reference: 21831473 - Trends Genet. 2011 Oct;27(10):433-9 – reference: 21804560 - Nat Biotechnol. 2011 Aug;29(8):742-9 – reference: 21550244 - Trends Cell Biol. 2011 Jun;21(6):354-61 – reference: 23124417 - Breast Cancer Res Treat. 2012 Dec;136(3):875-83 – reference: 19188922 - Nat Rev Genet. 2009 Mar;10(3):155-9 – reference: 21890647 - Genes Dev. 2011 Sep 15;25(18):1915-27 – reference: 24388988 - Biochem Biophys Res Commun. 2014 Jun 6;448(3):315-22 – reference: 14500907 - Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 – reference: 20979621 - Genome Biol. 2010;11(10):R106 – reference: 20887892 - Cell. 2010 Oct 1;143(1):46-58 – reference: 22350981 - J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):33-42 – reference: 19043537 - PLoS Comput Biol. 2008 Nov;4(11):e1000176 – reference: 18181038 - Cancer Invest. 2008 Feb;26(1):1-10 – reference: 21888627 - Breast Cancer Res. 2011;13(5):R85 – reference: 16683030 - PLoS Genet. 2006 Apr;2(4):e47 – reference: 22385965 - Cell. 2012 Mar 2;148(5):1015-28 – reference: 15914550 - Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20 – reference: 19204204 - J Clin Oncol. 2009 Mar 10;27(8):1160-7 – reference: 18600261 - Nature. 2008 Aug 7;454(7205):766-70 – reference: 10963602 - Nature. 2000 Aug 17;406(6797):747-52 – reference: 16199517 - Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 |
SSID | ssj0000547829 |
Score | 2.4832277 |
Snippet | Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 9864 |
SubjectTerms | Breast Neoplasms - classification Breast Neoplasms - genetics Breast Neoplasms - metabolism Cell Transformation, Neoplastic - genetics Female Gene Expression Humans MCF-7 Cells Receptor, ErbB-2 - biosynthesis Research Paper RNA, Long Noncoding - analysis RNA, Long Noncoding - biosynthesis RNA, Long Noncoding - classification RNA, Long Noncoding - genetics RNA, Messenger - genetics RNA, Messenger - metabolism Survival Rate |
Title | Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25296969 https://www.proquest.com/docview/1624934341 https://pubmed.ncbi.nlm.nih.gov/PMC4259443 |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA6uXryI4mt9LBG8eIhum0ebg4iIDwQ9iIt7K2ma6sLSarsL-u-dabu7rooghfbQNISZpPNNZvINIYcmDjSmBjGnOGfCjzkzwikW8iT0UqGtrXi67-7VTU_c9mV_djy6EWD5q2uH9aR6xfD4_e3jDBb8KS74UHH_JEcegypx-tgXUrTIUhUtwkS-BuzXTN8CzKGuwsxCM8DSvIlb_tbJvJ36AT6_51B-MUpXq2SlQZP0vFb_Gllw2Tp5wjVeuJc6NZ2ahnaE5ikd5tkzBYef2RxtFn24Py_pIKNVpT4aY4L6iFqcCAWdnJmk5TjGjdpyg_SuLh8vblhTP4FZofwRs9p5vtEAgWQ3ibmzPOVwNy7wZCJDA2BLuqSr0jRMfcQVUoO_IDX30lA5GfBNsghDctuEekjcJxKTWHjaAL0qEyI2NMpPlVVtcjKRVmQbcnGscTGM0MlA-UYz-UYo3zY5mn7xWhNr_NH2YKKACGY_hjRM5vJxGXkK3EcuwBS3yVatkGlvPoaU4WqTYE5V0wbIrD3_Jhu8VAzb8CPTQvCdf4xxlywDlhKVWevukcVRMXb7gFdGcYe0rvtep5qMn9xV7uw |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+analysis+of+long+non-coding+RNAs+in+human+breast+cancer+clinical+subtypes&rft.jtitle=Oncotarget&rft.au=Su%2C+Xiaoping&rft.au=Malouf%2C+Gabriel+G.&rft.au=Chen%2C+Yunxin&rft.au=Zhang%2C+Jianping&rft.date=2014-10-30&rft.issn=1949-2553&rft.eissn=1949-2553&rft.volume=5&rft.issue=20&rft.spage=9864&rft.epage=9876&rft_id=info:doi/10.18632%2Foncotarget.2454&rft.externalDBID=n%2Fa&rft.externalDocID=10_18632_oncotarget_2454 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon |